R&D channel feed – Endpoints News

R&D channel feed

Covid-19 manufacturing roundup: EMA clears 2 New England manufacturing sites for Covid-19 vaccine scale up; Incentives, tax breaks highlight South Korea's efforts to be vaccine powerhouse

4 years ago

Libtayo, chemo combo clears lung cancer trial two years early. But can it compete with Keytruda?

4 years ago

Moderna's Covid-19 vaccine sales to trail Pfizer's total significantly in 2021 and 2022

4 years ago

Merck's Keytruda takes home adjuvant win in melanoma, escalating early-line fight with Bristol Myers

4 years ago

A small vaccine developer favored by the UK government in Covid-19 touts a PhIII first in chikungunya

4 years ago

Shares of BeyondSpring skyrocket on new, positive cancer drug trial results

4 years ago

Pfizer puts the pressure on Eli Lilly's JAK inhibitor Olumiant with new data in alopecia areata

4 years ago

Samantha Du's Zai Lab inks surprising research collab with Schrödinger for DNA damage drug

4 years ago

Covid-19 roundup: Early fall approval date of Pfizer-BioNTech jab still anticipated; EU buys 200M doses of Novavax vaccine

4 years ago

Amgen halts a PhI for FLT3 BiTE while resuming dosing on another

4 years ago

Synbio unicorn Zymergen jettisons founding CEO, cuts guidance as customers report lead product doesn't work

4 years ago

Fast-growing BeiGene blueprints 42-acre R&D and manufacturing campus in the US, with plans to hire 'hundreds'

4 years ago

Eli Lilly: As donanemab filing approaches, execs 'even more confident' in data package

4 years ago

Sage drops a pair of late-stage tests for Biogen-partnered depression drug, raising the stakes on a final trial

4 years ago

J&J, GV back a new single-cell approach for tackling inflammatory diseases and hacking the tumor microenvironment

4 years ago

CytoDyn faces DOJ, SEC subpoenas after promoting failed Covid-19 drug

4 years ago

Tibsovo clears another hurdle for Servier, but can it make Agios' old drug profitable?

4 years ago

AbbVie, riding the Aduhelm afterglow, handpicks beta amyloid drug for further R&D as it bails on tau

4 years ago

BeiGene looks to carve out more space in the US market, setting up BTK drug for 2nd blood cancer nod

4 years ago

Biogen launches Phase IV trial to see just how well Aduhelm works in the real world

4 years ago

FDA sends 2nd noncompliance notice for company failing to post trial results as crackdown ramps up

4 years ago

Cavazzoni in the hot seat: House committee grills CDER director on neuro drugs

4 years ago

Gunning for Biogen’s multibillion dollar market, Eli Lilly cuts up another batch of Alzheimer’s data

4 years ago

Could a fourth lead drug finally bring Infinity an approval?

4 years ago

First page Previous page 162 163 164165166 167 168 Next page Last page